Zynerba Pharmaceuticals, a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, has named three seasoned pharmaceutical executives to its management team. Donna Gutterman, PharmD, is a consultant who will be vice president, medical affairs; Carol O'Neill will be vice president, development; and Suzanne Hanlon will be general counsel and vice president, human resources.
Gutterman, O'Neill and Hanlon will lead the medical, development and legal effort for Zynerba, the first and only transdermal cannabinoid therapeutic company, as it prepares to initiate phase 1 clinical studies in 2015 on ZYN001, a proprietary prodrug of THC transdermal patch, and ZYN002, a proprietary cannabidiol (CBD) transdermal gel.
Gutterman is a senior pharmaceutical executive with more than 30 years of experience in clinical development, medical affairs and commercialization in CNS therapy areas. During her career, she has led numerous successful clinical development programs, regulatory approvals and product launches. Previously, she was head of medical affairs for NuPathe through approval and pre-launch of its lead product, Zecuity, prior to the company being acquired by Teva Pharmaceuticals in 2014.
Gutterman worked in a variety of executive roles at GlaxoSmithKline. There she was instrumental in the clinical development of Imitrex and led the medical affairs teams in neurology and psychiatry. Additionally, she led several successful commercial product launches.
O'Neill has more than 18 years of development and operational experience in the biopharmaceutical industry. She has completed regulatory submissions and achieved approvals of new pharmaceutical products including a transdermal patch and a transdermal gel. Previously, she was vice president, development operations of NuPathe, where she successfully managed the development aspects of the clinical and nonclinical programs of the company's lead product, Zecuity. She also was senior director clinical operations at Auxilium Pharmaceuticals and senior director of operations analysis at Omnicare Clinical Research.
Hanlon is an attorney with 32 years of legal experience, particularly in public life sciences companies. She offers experience in contracts, licensing, compliance, clinical trials, regulatory, litigation, intellectual property and employment law. Previously, she was vice president, associate general counsel of NuPathe, where she successfully led the intellectual property strategy and the contracts effort in addition to managing the human resources function and she partnered with senior management to complete a successful IPO. She also was chief development counsel at Auxilium Pharmaceuticals and vice president of global contracts at Omnicare Clinical Research.